George Farmer
Stock Analyst at Scotiabank
(2.05)
# 3,043
Out of 4,996 analysts
71
Total ratings
42.11%
Success rate
-3.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by George Farmer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BMEA Biomea Fusion | Maintains: Sector Outperform | $30 → $10 | $2.10 | +376.19% | 4 | Aug 6, 2025 | |
| ACLX Arcellx | Maintains: Sector Outperform | $93 → $133 | $79.69 | +66.90% | 4 | Jul 31, 2025 | |
| INMB INmune Bio | Downgrades: Sector Underperform | $23 → $0.6 | $2.01 | -70.15% | 3 | Jul 1, 2025 | |
| URGN UroGen Pharma | Maintains: Sector Outperform | $23 → $47 | $18.34 | +156.27% | 1 | Jun 13, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Sector Perform | $16 → $17 | $15.68 | +8.42% | 4 | May 6, 2025 | |
| TARA Protara Therapeutics | Initiates: Sector Outperform | $12 | $4.25 | +182.35% | 1 | Apr 16, 2025 | |
| TPST Tempest Therapeutics | Downgrades: Sector Perform | $91 → $9 | $9.38 | -4.05% | 4 | Apr 10, 2025 | |
| ADAP Adaptimmune Therapeutics | Maintains: Sector Outperform | $3.15 → $1.4 | $0.15 | +852.38% | 2 | Mar 21, 2025 | |
| JANX Janux Therapeutics | Maintains: Sector Perform | $62 → $41 | $23.23 | +76.50% | 4 | Feb 28, 2025 | |
| NAMS NewAmsterdam Pharma Company | Maintains: Sector Outperform | $47 → $52 | $28.50 | +82.46% | 4 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $78 → $80 | $53.85 | +48.56% | 8 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $244 → $224 | $137.37 | +63.06% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $102 | $25.57 | +298.90% | 1 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $18 → $10 | $9.05 | +10.50% | 2 | Jan 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $439 → $715 | $712.03 | +0.42% | 5 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $20 → $23 | $6.16 | +273.38% | 2 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $20 | $4.11 | +386.62% | 1 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $70 → $76 | $33.37 | +127.75% | 4 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $13 | $2.73 | +376.19% | 1 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $109 | $24.49 | +345.08% | 3 | Nov 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $94 → $87 | $82.70 | +5.20% | 5 | Nov 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.23 | +1,379.82% | 1 | Oct 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $0.94 | +4,159.40% | 1 | Jul 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $27 | $39.04 | -30.84% | 3 | May 6, 2020 |
Biomea Fusion
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $30 → $10
Current: $2.10
Upside: +376.19%
Arcellx
Jul 31, 2025
Maintains: Sector Outperform
Price Target: $93 → $133
Current: $79.69
Upside: +66.90%
INmune Bio
Jul 1, 2025
Downgrades: Sector Underperform
Price Target: $23 → $0.6
Current: $2.01
Upside: -70.15%
UroGen Pharma
Jun 13, 2025
Maintains: Sector Outperform
Price Target: $23 → $47
Current: $18.34
Upside: +156.27%
Syndax Pharmaceuticals
May 6, 2025
Maintains: Sector Perform
Price Target: $16 → $17
Current: $15.68
Upside: +8.42%
Protara Therapeutics
Apr 16, 2025
Initiates: Sector Outperform
Price Target: $12
Current: $4.25
Upside: +182.35%
Tempest Therapeutics
Apr 10, 2025
Downgrades: Sector Perform
Price Target: $91 → $9
Current: $9.38
Upside: -4.05%
Adaptimmune Therapeutics
Mar 21, 2025
Maintains: Sector Outperform
Price Target: $3.15 → $1.4
Current: $0.15
Upside: +852.38%
Janux Therapeutics
Feb 28, 2025
Maintains: Sector Perform
Price Target: $62 → $41
Current: $23.23
Upside: +76.50%
NewAmsterdam Pharma Company
Feb 27, 2025
Maintains: Sector Outperform
Price Target: $47 → $52
Current: $28.50
Upside: +82.46%
Feb 20, 2025
Maintains: Sector Perform
Price Target: $78 → $80
Current: $53.85
Upside: +48.56%
Feb 13, 2025
Maintains: Sector Outperform
Price Target: $244 → $224
Current: $137.37
Upside: +63.06%
Feb 13, 2025
Initiates: Sector Outperform
Price Target: $102
Current: $25.57
Upside: +298.90%
Jan 8, 2025
Maintains: Sector Perform
Price Target: $18 → $10
Current: $9.05
Upside: +10.50%
Nov 5, 2024
Upgrades: Sector Outperform
Price Target: $439 → $715
Current: $712.03
Upside: +0.42%
Oct 18, 2024
Maintains: Sector Outperform
Price Target: $20 → $23
Current: $6.16
Upside: +273.38%
Sep 30, 2024
Initiates: Sector Outperform
Price Target: $20
Current: $4.11
Upside: +386.62%
Aug 12, 2024
Maintains: Sector Outperform
Price Target: $70 → $76
Current: $33.37
Upside: +127.75%
Mar 14, 2024
Initiates: Sector Outperform
Price Target: $13
Current: $2.73
Upside: +376.19%
Nov 17, 2020
Downgrades: Market Perform
Price Target: $109
Current: $24.49
Upside: +345.08%
Nov 6, 2020
Maintains: Market Perform
Price Target: $94 → $87
Current: $82.70
Upside: +5.20%
Oct 27, 2020
Initiates: Outperform
Price Target: $33
Current: $2.23
Upside: +1,379.82%
Jul 20, 2020
Initiates: Outperform
Price Target: $40
Current: $0.94
Upside: +4,159.40%
May 6, 2020
Maintains: Market Perform
Price Target: $20 → $27
Current: $39.04
Upside: -30.84%